在帕金森病患者中重新使用赛莱科西布作为辅助疗法:一种新的治疗黎明:随机对照试点研究
Mohannad O Khrieba1, Sahar K Hegazy2, Wessam Mustafa3
1Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt. mkhrieba@horus.edu.eg.
Inflammopharmacology
|September 28, 2024
概括
切莱科克西布作为帕金森病 (PD) 的附加治疗方法显示出希望. 这项研究发现,切莱科西布降低了神经炎症标志物,并改善了PD患者的UPDRS得分.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,其特征是运动症状.
- 神经炎症越来越被认为是PD病变发生的一个关键因素.
- 非类固醇抗炎药物 (NSAIDs) 正在探索它们在缓解PD中神经炎症的潜力.
研究的目的:
- 评估塞莱科克西布作为帕金森病患者辅助治疗的疗效.
- 评估赛莱科西布对PD患者特定生物标志物和临床结果的影响.
主要方法:
- 一项随机对照研究,涉及60名接受标准治疗 (莱沃多巴/卡比多巴) 的PD门诊患者.
- 患者被分配到单独标准治疗 (对照) 或标准治疗加CELECOXIB.
- 评估包括统一帕金森病评级表 (UPDRS) 和生物标志物的评估 (α-Syn,TNF-α,TLR-4,Nrf-2,BDNF) 在基线和6个月后.
主要成果:
- 与对照组相比,切莱科西布组显示TLR-4,TNF-α和α-synuclein水平显著降低.
- 在赛莱科克西布组中观察到BDNF和Nrf-2水平的显著增加.
- 统一帕金森病评分表 (UPDRS) 的评分在接受塞莱科克西布治疗的患者中显著下降.
结论:
- 塞莱科克西布显示出作为治疗帕金森病的有效辅助疗法的潜力.
- 这些发现表明,赛莱科克西布可能有助于减少神经炎症,并改善PD患者的临床症状.
相关概念视频
01:24Parkinson's Disease: Treatment
233
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
233
01:30Adrenergic Agonists: Therapeutic Uses
743
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
743
01:15Parkinson's Disease: Overview
492
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
492
01:18Adrenergic Agonists: Therapeutic Classification
743
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
743
01:28Adrenergic Agonists: Mixed-Action Agents
678
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
678
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
702
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
702